Antisoma (ASM)
market vs.
industry GROWTH & VALUE
| Trailing 12m | ||||
| PE Ratio (ttm) | 17.6 |
|
|
|
| PEG Ratio (ttm) |
|
|
||
| EPS Growth (ttm) | % |
|
|
|
| Dividend Yield (ttm) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 0.84 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 30th Jun | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | TTM | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | ||||||||||
| Operating Profit | £m | ||||||||||
| Net Profit | £m | ||||||||||
| EPS Reported | p | ||||||||||
| EPS Normalised | p | ||||||||||
| EPS Growth | % | ||||||||||
| PE Ratio | x | ||||||||||
| PEG | x | ||||||||||
| Profitability | |||||||||||
| Operating Margin | % | ||||||||||
| ROA | % | ||||||||||
| ROCE | % | ||||||||||
| ROE | % | ||||||||||
| Cashflow | |||||||||||
| Op. Cashflow ps | p | ||||||||||
| Capex ps | p | ||||||||||
| Free Cashflow ps | p | ||||||||||
| Dividends | |||||||||||
| Dividend ps | p | ||||||||||
| Dividend Growth | % | ||||||||||
| Dividend Yield | % | ||||||||||
| Dividend Cover | x | ||||||||||
| Balance Sheet | |||||||||||
| Cash etc | £m | ||||||||||
| Working Capital | £m | ||||||||||
| Net Fixed Assets | £m | ||||||||||
| Net Debt | £m | ||||||||||
| Book Value | £m | ||||||||||
| Average Shares | m | ||||||||||
| Book Value ps | p | -27.9% | |||||||||
FINANCIAL BRIEF: For the six months ended 31 December 2012, Antisoma plc revenues increased from L0K to L68K. Net loss decreased 89% to L30K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest Payable decrease of 95% to L12K (expense), Finance Income increase of 22% to L66K (income). more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Dec '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: |
Antisoma plc (Antisoma) is as an investing company. The principal activity of the Company is the investment in and growth and development of businesses. Antisoma's segment includes Portfolio Investment return. All Portfolio investment return is derived from the United Kingdom and other income from the United States. Antisoma's equity interest in an investment may range from a minority position to 100% ownership and the interest may be either quoted or unquoted.
Directors: Christopher Hill (Secy.) ,
No. of Employees: 43 No. of Shareholders: n/a
| Last Annual | June 30th, 2012 |
| Last Interim | December 31st, 2012 |
| Shares in Issue | 643,692,047 |
| Free Float | 312.1m (48.5%) |
| Sector | Financials |
| Industry | Collective Investments |
| Index | FTSE Aim All Share, |
| Exchange |
London Stock Exchange (AIM) |
| Eligible for | an ISA? a SIPP? |
| Address | Mitre House,160 Aldersgate Street, LONDON, EC1A 4DD, United Kingdom |
| Web | http://www.antisoma.com |
| Phone | +44 20 70997268 |
| Contact | Raymond Spencer (Secy.) |
| Registrar | Capita Registrars |
| Auditors | PricewaterhouseCoopers LLP |
| 16th May | ASMI ANNOUNCES VOTING RESULTS OF ANNUAL GENERAL ME |
| 23rd Apr | ASM INTERNATIONAL N.V. REPORTS FIRST QUARTER 2013 |
| 23rd Apr | News |
| 16th Apr | News |
| 10th Apr | Placing Agreement with Silence Therapeutics plc |
| 4th Apr | ASM INTERNATIONAL N.V. ANNOUNCES AVAILABILITY OF A |
Recent ↓
